Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Neurocritical Care
Published in: Neurocritical Care 2/2011

01-10-2011 | Review

Magnesium Sulfate Administration in Subarachnoid Hemorrhage

Authors: Jose I. Suarez, The Participants in the International Multidisciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage

Published in: Neurocritical Care | Issue 2/2011

Login to get access

Abstract

Magnesium offers theoretic vascular and neuroprotective benefits for patients with subarachnoid hemorrhage. An electronic literature search was conducted to identify original research studies describing intravenous magnesium treatment in patients with SAH published in English between January 1990 and October 2010. Seventeen articles were identified and reviewed, including one phase III randomized-controlled clinical trial and six phase II randomized-controlled trials. Study quality was low for most of the included studies, with the phase III trial considered to be of moderate quality. Due to inconsistently reported benefits and the occurrence of side effects, phase II data suggested that intravenous magnesium for SAH provided either no overall net benefit or uncertain trade-offs. Benefit was likewise not supported in the single phase III clinical trial.
Literature
1.
Saddeh M. Action of magnesium sulfate in the treatment of preeclampsia-eclampsia. Stroke. 1989;20:1273–5.CrossRef
2.
Taccone FS. Vasodilation and neuroprotection: the magnesium saga in subarachnoid hemorrhage. Crit Care Med. 2010;38:1382–3.PubMedCrossRef
3.
Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. Neuroprotective effects of preischemia intra-arterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg. 1996;85:117–24.PubMedCrossRef
4.
van den Bergh WM, Dijkhuizen RM, Rnkel GJ. Potentials of magnesium treatment in subarachnoid hemorrhage. Magnes Res. 2004;17:301–13.PubMed
5.
Ortega-Gutierrez S, Mayer SA. Is the magnesium era for aneurysmal subarachnoid hemorrhage over? Curr Neurol Neurosci Rep. 2010;10:420–2.PubMedCrossRef
6.
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.PubMedCrossRef
7.
Wong GKC, Poon WS, Chan MTV, Boet R, Gin T, Ng SCP, Zee BCY, For the IMASH Investigators. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke. 2010;41:921–6.PubMedCrossRef
8.
Westermaier T, Stetter C, Vince GH, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. 2010;38:1284–90.PubMedCrossRef
9.
Wong GKC, Chan MTV, Boet R, Poon WS, Gin T. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol. 2006;18:142–8.PubMedCrossRef
10.
van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36:1011–5.PubMedCrossRef
11.
Schmid-Elsaesser R, Kunz M, Zausinger S, Prueckner S, Briegel J, Steiger HJ. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. Neurosurgery. 2006;58:1054–65.PubMedCrossRef
12.
Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol. 2008;69:33–9.PubMedCrossRef
13.
Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;96:510–4.PubMedCrossRef
14.
van den Bergh WM, Albrecht KW, Berkelbach JW, van der Sprenkel B, Rinkel GJE. Magnesium therapy after aneurysmal subarachnoid haemorrhage dose-finding study for long term treatment. Acta Neurochir. 2003;145:195–9.CrossRef
15.
Stippler M, Crago E, Levy EI, et al. Magnesium infusion for vasospasm prophylaxis after subarachnoid hemorrhage. J Neurosurg. 2006;105:723–9.PubMedCrossRef
16.
Boet R, Mee E. Magnesium sulfate in the management of patients with Fisher Grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery. 2000;47:602–7.PubMed
17.
Brewer RP, Parra A, Lynch J, Chilukuri V, Borel CO. Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2001;13:202–6.PubMedCrossRef
18.
Mori K, Yamamoto T, Nakao Y, et al. Initial clinical experience of vasodilatory effect of intracisternal infusion of magnesium sulfate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2009;49:139–45.CrossRef
19.
Friedlich D, Agner C, Boulos AS, et al. Retrospective analysis of parenteral magnesium sulfate administration in decreased incidence of clinical and neuroradiological cerebral vasospasm: a single center experience. Neurol Res. 2009;31:621–5.PubMedCrossRef
20.
Kerz T, Victor A, Beyer C, Trapp I, Heid F, Reisch R. A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ischemia and mortality. Neurol Res. 2008;30:893–7.PubMedCrossRef
21.
Yahia AM, Kirmani JF, Qureshi AI, Guterman LR, Hopkins LN. The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2005;3:16–23.PubMedCrossRef
22.
Shah QA, Memon MZ, Suri MFK, et al. Super-selective intra-arterial magnesium sulfate in combination with nicardipine for the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Neurocrit Care. 2009;11:190–8.PubMedCrossRef
23.
Barile M, van de Wyngaert F, Mbia JJE, et al. Intravenous magnesium sulfate administration in a patient with refractory vasospasm following subarachnoid hemorrhage. Intensive Care Med. 2003;29:1182–5.PubMedCrossRef
Metadata
Title
Magnesium Sulfate Administration in Subarachnoid Hemorrhage
Authors
Jose I. Suarez
The Participants in the International Multidisciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage
Publication date
01-10-2011
Publisher
Humana Press Inc
Published in
Neurocritical Care / Issue 2/2011
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-011-9603-y

Other articles of this Issue 2/2011

Neurocritical Care 2/2011 Go to the issue

Review

Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage: Recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference

Review

Hemodynamic Management of Subarachnoid Hemorrhage

Review

Summary of Evidence on Immediate Statins Therapy Following Aneurysmal Subarachnoid Hemorrhage

Review

Cardiovascular and Pulmonary Complications of Aneurysmal Subarachnoid Hemorrhage

Review

Fever Management in SAH

Review

Deep Venous Thrombosis Prophylaxis